US65488A1016

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimers Disease at AD/PD 2026

March 10, 2026 08:05 ET  | Source: NKGen Biotech, Inc. SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen…

2 days ago

NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

July 10, 2025 16:30 ET  | Source: NKGen Biotech, Inc. SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen…

8 months ago